Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition

Langerhans cell histiocytosis (LCH) is a clonally derived neoplasm with a highly variable clinical course. Although LCH was once considered a disorder of immune regulation, the identification of activating mutations in the proto-oncogene BRAF-V600E in ~50%-60% of cases and MEK and ERK phosphorylatio...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Hematology 2015-12, Vol.2015 (1), p.565-570
Hauptverfasser: Abla, Oussama, Weitzman, Sheila
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 570
container_issue 1
container_start_page 565
container_title Hematology
container_volume 2015
creator Abla, Oussama
Weitzman, Sheila
description Langerhans cell histiocytosis (LCH) is a clonally derived neoplasm with a highly variable clinical course. Although LCH was once considered a disorder of immune regulation, the identification of activating mutations in the proto-oncogene BRAF-V600E in ~50%-60% of cases and MEK and ERK phosphorylation in 100% of examined cases, has changed the definition of LCH to a dendritic cell neoplasm with a strong inflammatory component. Current international LCH trials are focused on further improving the outcome of high-risk multisystem LCH patients, by decreasing the reactivation rate, optimizing early salvage regimens, and preventing late sequelae. Anecdotal responses to vemurafenib, a BRAF-V600E inhibitor, have been reported in a few cases of LCH and Erdheim-Chester disease. However, the development of resistance, as well as the potential risks of cutaneous and pancreatic cancers in patients with BRAF-V600E-mutated melanoma treated with single inhibitors, suggest the need for prospective trials with BRAF inhibitors, alone or in combination with other inhibitors of this pathway, for patients with refractory or multiply-relapsed LCH. The recent discovery of somatic mutations in ARAF and in MAP2K1, which lead to activation of the RAS-RAF-MEK -ERK pathway in the setting of wild-type BRAF, as well as the finding that activating mutation in MAP2K1 are relatively insensitive to MEK inhibitors, suggest that a more detailed understanding of this pathway in LCH may be necessary for the development of more effective targeted therapies.
doi_str_mv 10.1182/asheducation-2015.1.565
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1744659635</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1744659635</sourcerecordid><originalsourceid>FETCH-LOGICAL-c379t-e4e77271d02b50934f6ac6463ad5647845966cf77108975230e14b9acc6396363</originalsourceid><addsrcrecordid>eNpNkE1PwjAYxxujEUS_gu7oZdD3rt6QgBgxGoPnpus6V7MXbLcD394tIPH0PIf_W34A3CE4RSjBMx0Km3VGt66pYwwRm6Ip4-wMjBHDMKYkIeenX6IRuArhG0JECcaXYIQ5J0IIMgbrrbe6rWzdRk0ebXT9ZX2h6xAZW5ZR4ULfYPZtE1x4iHxT2kH2-DFfzV7n7y-RqwuXumHFNbjIdRnszfFOwOdquV2s483b0_NivokNEbKNLbVCYIEyiFMGJaE514ZTTnTGOBUJZZJzkwuBYCIFwwRaRFOpjeFEcsLJBNwfcne--elsaFXlwjBW17bpgkKCUt6HENZLxUFqfBOCt7naeVdpv1cIqgGj-o9RDRgVUj3G3nl7LOnSymYn3x838gueAnAY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1744659635</pqid></control><display><type>article</type><title>Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition</title><source>MEDLINE</source><source>NCBI_PubMed Central(免费)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Abla, Oussama ; Weitzman, Sheila</creator><creatorcontrib>Abla, Oussama ; Weitzman, Sheila</creatorcontrib><description>Langerhans cell histiocytosis (LCH) is a clonally derived neoplasm with a highly variable clinical course. Although LCH was once considered a disorder of immune regulation, the identification of activating mutations in the proto-oncogene BRAF-V600E in ~50%-60% of cases and MEK and ERK phosphorylation in 100% of examined cases, has changed the definition of LCH to a dendritic cell neoplasm with a strong inflammatory component. Current international LCH trials are focused on further improving the outcome of high-risk multisystem LCH patients, by decreasing the reactivation rate, optimizing early salvage regimens, and preventing late sequelae. Anecdotal responses to vemurafenib, a BRAF-V600E inhibitor, have been reported in a few cases of LCH and Erdheim-Chester disease. However, the development of resistance, as well as the potential risks of cutaneous and pancreatic cancers in patients with BRAF-V600E-mutated melanoma treated with single inhibitors, suggest the need for prospective trials with BRAF inhibitors, alone or in combination with other inhibitors of this pathway, for patients with refractory or multiply-relapsed LCH. The recent discovery of somatic mutations in ARAF and in MAP2K1, which lead to activation of the RAS-RAF-MEK -ERK pathway in the setting of wild-type BRAF, as well as the finding that activating mutation in MAP2K1 are relatively insensitive to MEK inhibitors, suggest that a more detailed understanding of this pathway in LCH may be necessary for the development of more effective targeted therapies.</description><identifier>ISSN: 1520-4391</identifier><identifier>EISSN: 1520-4383</identifier><identifier>DOI: 10.1182/asheducation-2015.1.565</identifier><identifier>PMID: 26637773</identifier><language>eng</language><publisher>United States</publisher><subject>Clinical Trials as Topic ; Erdheim-Chester Disease - genetics ; Histiocytosis, Langerhans-Cell - therapy ; Humans ; Imatinib Mesylate - therapeutic use ; Indoles - therapeutic use ; Inflammation ; MAP Kinase Kinase 1 - genetics ; MAP Kinase Signaling System ; Mutation ; Phosphorylation ; Prospective Studies ; Proto-Oncogene Proteins B-raf - antagonists &amp; inhibitors ; Proto-Oncogene Proteins B-raf - genetics ; Recurrence ; Risk ; Sulfonamides - therapeutic use</subject><ispartof>Hematology, 2015-12, Vol.2015 (1), p.565-570</ispartof><rights>2015 by The American Society of Hematology. All rights reserved.</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c379t-e4e77271d02b50934f6ac6463ad5647845966cf77108975230e14b9acc6396363</citedby><cites>FETCH-LOGICAL-c379t-e4e77271d02b50934f6ac6463ad5647845966cf77108975230e14b9acc6396363</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26637773$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abla, Oussama</creatorcontrib><creatorcontrib>Weitzman, Sheila</creatorcontrib><title>Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition</title><title>Hematology</title><addtitle>Hematology Am Soc Hematol Educ Program</addtitle><description>Langerhans cell histiocytosis (LCH) is a clonally derived neoplasm with a highly variable clinical course. Although LCH was once considered a disorder of immune regulation, the identification of activating mutations in the proto-oncogene BRAF-V600E in ~50%-60% of cases and MEK and ERK phosphorylation in 100% of examined cases, has changed the definition of LCH to a dendritic cell neoplasm with a strong inflammatory component. Current international LCH trials are focused on further improving the outcome of high-risk multisystem LCH patients, by decreasing the reactivation rate, optimizing early salvage regimens, and preventing late sequelae. Anecdotal responses to vemurafenib, a BRAF-V600E inhibitor, have been reported in a few cases of LCH and Erdheim-Chester disease. However, the development of resistance, as well as the potential risks of cutaneous and pancreatic cancers in patients with BRAF-V600E-mutated melanoma treated with single inhibitors, suggest the need for prospective trials with BRAF inhibitors, alone or in combination with other inhibitors of this pathway, for patients with refractory or multiply-relapsed LCH. The recent discovery of somatic mutations in ARAF and in MAP2K1, which lead to activation of the RAS-RAF-MEK -ERK pathway in the setting of wild-type BRAF, as well as the finding that activating mutation in MAP2K1 are relatively insensitive to MEK inhibitors, suggest that a more detailed understanding of this pathway in LCH may be necessary for the development of more effective targeted therapies.</description><subject>Clinical Trials as Topic</subject><subject>Erdheim-Chester Disease - genetics</subject><subject>Histiocytosis, Langerhans-Cell - therapy</subject><subject>Humans</subject><subject>Imatinib Mesylate - therapeutic use</subject><subject>Indoles - therapeutic use</subject><subject>Inflammation</subject><subject>MAP Kinase Kinase 1 - genetics</subject><subject>MAP Kinase Signaling System</subject><subject>Mutation</subject><subject>Phosphorylation</subject><subject>Prospective Studies</subject><subject>Proto-Oncogene Proteins B-raf - antagonists &amp; inhibitors</subject><subject>Proto-Oncogene Proteins B-raf - genetics</subject><subject>Recurrence</subject><subject>Risk</subject><subject>Sulfonamides - therapeutic use</subject><issn>1520-4391</issn><issn>1520-4383</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkE1PwjAYxxujEUS_gu7oZdD3rt6QgBgxGoPnpus6V7MXbLcD394tIPH0PIf_W34A3CE4RSjBMx0Km3VGt66pYwwRm6Ip4-wMjBHDMKYkIeenX6IRuArhG0JECcaXYIQ5J0IIMgbrrbe6rWzdRk0ebXT9ZX2h6xAZW5ZR4ULfYPZtE1x4iHxT2kH2-DFfzV7n7y-RqwuXumHFNbjIdRnszfFOwOdquV2s483b0_NivokNEbKNLbVCYIEyiFMGJaE514ZTTnTGOBUJZZJzkwuBYCIFwwRaRFOpjeFEcsLJBNwfcne--elsaFXlwjBW17bpgkKCUt6HENZLxUFqfBOCt7naeVdpv1cIqgGj-o9RDRgVUj3G3nl7LOnSymYn3x838gueAnAY</recordid><startdate>20151205</startdate><enddate>20151205</enddate><creator>Abla, Oussama</creator><creator>Weitzman, Sheila</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20151205</creationdate><title>Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition</title><author>Abla, Oussama ; Weitzman, Sheila</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c379t-e4e77271d02b50934f6ac6463ad5647845966cf77108975230e14b9acc6396363</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Clinical Trials as Topic</topic><topic>Erdheim-Chester Disease - genetics</topic><topic>Histiocytosis, Langerhans-Cell - therapy</topic><topic>Humans</topic><topic>Imatinib Mesylate - therapeutic use</topic><topic>Indoles - therapeutic use</topic><topic>Inflammation</topic><topic>MAP Kinase Kinase 1 - genetics</topic><topic>MAP Kinase Signaling System</topic><topic>Mutation</topic><topic>Phosphorylation</topic><topic>Prospective Studies</topic><topic>Proto-Oncogene Proteins B-raf - antagonists &amp; inhibitors</topic><topic>Proto-Oncogene Proteins B-raf - genetics</topic><topic>Recurrence</topic><topic>Risk</topic><topic>Sulfonamides - therapeutic use</topic><toplevel>online_resources</toplevel><creatorcontrib>Abla, Oussama</creatorcontrib><creatorcontrib>Weitzman, Sheila</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abla, Oussama</au><au>Weitzman, Sheila</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition</atitle><jtitle>Hematology</jtitle><addtitle>Hematology Am Soc Hematol Educ Program</addtitle><date>2015-12-05</date><risdate>2015</risdate><volume>2015</volume><issue>1</issue><spage>565</spage><epage>570</epage><pages>565-570</pages><issn>1520-4391</issn><eissn>1520-4383</eissn><abstract>Langerhans cell histiocytosis (LCH) is a clonally derived neoplasm with a highly variable clinical course. Although LCH was once considered a disorder of immune regulation, the identification of activating mutations in the proto-oncogene BRAF-V600E in ~50%-60% of cases and MEK and ERK phosphorylation in 100% of examined cases, has changed the definition of LCH to a dendritic cell neoplasm with a strong inflammatory component. Current international LCH trials are focused on further improving the outcome of high-risk multisystem LCH patients, by decreasing the reactivation rate, optimizing early salvage regimens, and preventing late sequelae. Anecdotal responses to vemurafenib, a BRAF-V600E inhibitor, have been reported in a few cases of LCH and Erdheim-Chester disease. However, the development of resistance, as well as the potential risks of cutaneous and pancreatic cancers in patients with BRAF-V600E-mutated melanoma treated with single inhibitors, suggest the need for prospective trials with BRAF inhibitors, alone or in combination with other inhibitors of this pathway, for patients with refractory or multiply-relapsed LCH. The recent discovery of somatic mutations in ARAF and in MAP2K1, which lead to activation of the RAS-RAF-MEK -ERK pathway in the setting of wild-type BRAF, as well as the finding that activating mutation in MAP2K1 are relatively insensitive to MEK inhibitors, suggest that a more detailed understanding of this pathway in LCH may be necessary for the development of more effective targeted therapies.</abstract><cop>United States</cop><pmid>26637773</pmid><doi>10.1182/asheducation-2015.1.565</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1520-4391
ispartof Hematology, 2015-12, Vol.2015 (1), p.565-570
issn 1520-4391
1520-4383
language eng
recordid cdi_proquest_miscellaneous_1744659635
source MEDLINE; NCBI_PubMed Central(免费); EZB-FREE-00999 freely available EZB journals
subjects Clinical Trials as Topic
Erdheim-Chester Disease - genetics
Histiocytosis, Langerhans-Cell - therapy
Humans
Imatinib Mesylate - therapeutic use
Indoles - therapeutic use
Inflammation
MAP Kinase Kinase 1 - genetics
MAP Kinase Signaling System
Mutation
Phosphorylation
Prospective Studies
Proto-Oncogene Proteins B-raf - antagonists & inhibitors
Proto-Oncogene Proteins B-raf - genetics
Recurrence
Risk
Sulfonamides - therapeutic use
title Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T09%3A14%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20Langerhans%20cell%20histiocytosis:%20role%20of%20BRAF/MAPK%20inhibition&rft.jtitle=Hematology&rft.au=Abla,%20Oussama&rft.date=2015-12-05&rft.volume=2015&rft.issue=1&rft.spage=565&rft.epage=570&rft.pages=565-570&rft.issn=1520-4391&rft.eissn=1520-4383&rft_id=info:doi/10.1182/asheducation-2015.1.565&rft_dat=%3Cproquest_cross%3E1744659635%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1744659635&rft_id=info:pmid/26637773&rfr_iscdi=true